Comparative Pharmacology
Head-to-head clinical analysis: LITFULO versus TOFACITINIB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LITFULO versus TOFACITINIB.
LITFULO vs TOFACITINIB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Litfulo (ritlecitinib) is a Janus kinase (JAK) inhibitor that selectively inhibits JAK3 and to a lesser extent TEC family kinases, thereby modulating the signaling pathways involved in the immune response.
Janus kinase (JAK) inhibitor, primarily inhibiting JAK1 and JAK3, thereby modulating the JAK-STAT signaling pathway to reduce cytokine production and immune cell activation.
50 mg orally once daily, with or without food.
5 mg orally twice daily; extended-release formulation 11 mg orally once daily. For rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and polyarticular course juvenile idiopathic arthritis. For ulcerative colitis, induction: 10 mg orally twice daily for 8 weeks, then maintenance 5 mg twice daily.
None Documented
None Documented
Clinical Note
moderateTofacitinib + Digoxin
"Tofacitinib may increase the bradycardic activities of Digoxin."
Clinical Note
moderateTofacitinib + Bendroflumethiazide
"Tofacitinib may increase the bradycardic activities of Bendroflumethiazide."
Clinical Note
moderateTofacitinib + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Tofacitinib."
Clinical Note
moderateTofacitinib + Erythromycin
Terminal elimination half-life is approximately 50 hours (range 40–60 h), supporting once-daily or twice-daily dosing with steady-state achieved within 10–14 days.
Terminal half-life approximately 3.3 hours in healthy volunteers. In patients with rheumatoid arthritis, effective half-life ~3-6 hours due to reversible binding to JAK enzymes. No significant accumulation at steady state.
Primarily excreted unchanged in feces (≈66%) via biliary secretion, with renal excretion accounting for ≈23% as unchanged drug and metabolites; <1% excreted in urine as unchanged parent compound.
Primarily renal (70%) with 30% excreted unchanged in urine. Fecal elimination accounts for 20% (<1% unchanged). Minor biliary excretion.
Category C
Category D/X
JAK Inhibitor
JAK Inhibitor
"The metabolism of Erythromycin can be decreased when combined with Tofacitinib."